| Literature DB >> 24416378 |
Ping Liu1, Yi Liu2, Jianning Wang3, Yang Guo1, Yujie Zhang1, Shuiqing Xiao1.
Abstract
Fusobacterium nucleatum is one of the most abundant gram-negative bacilli colonizing the subgingival plaque and closely associated with periodontal disease. However it is unclear whether F. nucleatum is involved in gingival inflammation under orthodontic appliance. A novel adhesin, FadA, which is unique to oral Fusobacteria, is required for F. nucleatum binding and invasion to epithelial cells and thus may play an important role in colonization of Fusobacterium in the host. In this study, we evaluated the prevalence of F. nucleatum and its virulence factor FadA adhesion gene (fadA) in 169 subgingival biofilm samples from 55 cases of gingivitis patients with orthodontic appliances, 49 cases of gingivitis patients without orthodontic treatment, 35 cases of periodontitis patients and 30 cases of periodontally healthy people via PCR. The correlations between the F. nucleatum/fadA and gingivitis index(GI)was also analyzed. The detection rate of F. nucleatum/fadA in periodontitis group and non-orthodontic gingivitis group was higher than the other two groups (p<0.01) while it was higher in orthodontic gingivitis group than in health people (p<0.05). An obviously positive correlation was observed between the prevalence of F. nucleatum/fadA and GI. F. nucleatum carrying fadA may be more closely related to the development of gingivitis and periodontal disease compared with orthodontic gingivitis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24416378 PMCID: PMC3887018 DOI: 10.1371/journal.pone.0085280
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Detection and distribution of F. nucleatum/fadA.
a. Detection of F. nucleatum in clinical subgingival biofilm samples. M:Marker;lane 1:positive control of F. nucleatum ATCC25586;lane 2:blank; lane 3∼10:positive clinical samples;lane 11 and12:negative clinical samples; b. Detection of fadA in clinical subgingival biofilm samples. M:Marker;lane 1:positive control of F. nucleatum ATCC25586;lane 2:blank;lane 3,4,6∼10:positive clinical samples;lane 5: negative clinical sample; c. Distribution of F. nucleatum in four groups. d. Distribution of fadA in four groups. ** P<0.01 between GI 2 and GI 0 in PG and NOG (c, d) (Chi-squared test).
Prevalence of F. nucleatum and fadA among four groups.
| Groups | Cases(n) |
|
| ||
| counts | Detection rate(%) | counts | Detection rate(%) | ||
| CG | 30 | 14 | 46.67 | 10 | 33.33 |
| OG | 55 | 38 | 69.09 | 32 | 58.18 |
| NOG | 49 | 41 | 83.67** | 34 | 69.39** |
| PG | 35 | 29 | 82.86** | 25 | 71.43** |
| Total | 169 | 122 | 72.19 | 101 | 59.76 |
P<0.05 between OG/NOG/PG and CG; **P<0.01 between OG/NOG/PG and CG (Chi-squared test).
Figure 2Sequencing chromatograms from F. nucleatum PCR product.
a. F primer; b. R primer; c. DNA sequencing and BLAST analysis results.